



# ERT CARDIAC SAFETY

Monitor every heartbeat with precision and ensure safety


## NAVIGATE CARDIAC SAFETY COMPLEXITIES

Cardiac safety concerns are among the leading reasons that promising drugs are delayed or abandoned in development and not brought to market. Safety issues coupled with a complex regulatory landscape mean you need expert guidance to minimize risks and bring clinical treatments to market faster — and with confidence.

## INCREASE PATIENT SAFETY WITH CENTRALIZED SOLUTIONS

Be confident in your data with centralized solutions. Our dedicated team focuses on studying ECGs which means fewer queries and no missing data. With all your data in one place, you can save time and navigate the unexpected. You are not limited to a “one-size-fits-all” approach when you partner with us on cardiac safety. Instead, empower your studies with rapid configuration and analysis, real-time trial visibility and additional endpoints integrated into ERT EXPERT®, our proprietary technology platform.

**CARDIAC SAFETY ISSUES ARE A KEY DRIVER IN DRUG DEVELOPMENT DELAYS AND ABANDONMENT**



**EMPOWER YOUR STUDIES WITH STANDARD ASSESSMENTS, HIGH-QUALITY DATA AND CENTRALIZED MONITORING**

## HAVE CONFIDENCE IN YOUR CARDIAC SAFETY STRATEGY

Access enhanced cardiac safety services that leverage the capabilities of iCardiac Technologies and Biomedical Systems, both of which were acquired by ERT in 2017. Our team of scientists and clinicians can select the best strategy for analyzing cardiac safety and determine the best devices to collect high-quality data for your trial.



### Minimize risk and make smart decisions

Collaborate with our Phase 1 QT Center of Excellence to gain actionable and highly-reliable information about the cardiac safety profile of drug candidates. Confidently navigate unexpected issues throughout your early-phase trial with our Expert Precision QT (EPQT) approach.



### Critical, centralized expertise for global studies

Make critical decisions in late-phase studies with our SafePatient ECG solution. Minimize risk and increase confidence in your complex global studies with real-time access to centralized study data.



### Certified sites trained and qualified

Increase confidence in high-quality data with an ERT Certified Site for Phase 1 studies, which has been trained and qualified based on specific criteria. Certification includes meeting pre-certification requirements, signing a site program agreement, identifying site champions to receive test conduct training, completing a quality questionnaire and providing applicable documents.

### PROVIDING CARDIAC SAFETY SERVICES FOR:

**500+ drug approvals**

**200K+ overall sites**

**3M+ patients**

**3600+ early-phase studies**

**5400+ late-phase studies**

## OUR EXPERIENCE DRIVES A BETTER EXPERIENCE FOR YOU

Position your trial for success with our cardiac safety solutions, which provide you with the highest quality patient data on time — and in real-time.

**99.5%**

**On-time ECG file  
transfer acceptance**

**99.7%**

**On-time ECG  
equipment shipments**

**99.9%**

**On-time replacement  
shipments**

**99.8%**

**On-time ECG reporting  
to study sites**

**98.5%**

**High-quality  
ECGs**

Monitor every heartbeat with precision and ensure safety.

To learn more, go to [ert.com](https://ert.com) or email [info@ert.com](mailto:info@ert.com).

## ABOUT ERT

ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what's next, so we can adapt without compromising standards.

Powered by the company's EXPERT® technology platform, ERT's solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2014, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions in 10,000+ studies spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly — and with confidence.